The effect of anti-calcitonin gene-related peptide (CGRP) receptor antibodies on the headache inducing properties of CGRP and cilostazol in migraine patients

Rigshospitalet Glostrup0 个研究点目标入组 72 人开始时间: 2020年3月27日最近更新: 2021年6月14日

适应症

试验速览

暂无简介。

•(1) Patients with migraine with or without aura according to ICHD-3 of both sexes with a frequency of =4 migraine days per month
•(2) 18-60 years old
•(3) 50-100 kg weight
•(4) Participants of childbearing potential must use safe contraception (birth control) or be sexually abstinent
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 72
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•(1) Any other primary headache disorder according to ICHD-3 except for tension-type headache
•(2) Any secondary headache disorder according to ICHD-3
•(3) Migraine attack during the preceding 48 hours on provocation day(s)
•(4) Headache during the preceding 24 hours on provocation day(s)
•(4) Treatment with mAbs or participation in clinical trials with mAbs during the preceding year.
•(5) Daily consumption of any other drug/medication than oral contraception (birth control)
•(6) Consumption of any other drug/medication later than four times the plasma half-time of the drug on provocation day except for oral contraception.
•(7) Pregnant or active breastfeeding participants.
•(8) Any cardiovascular diseases including cerebrovascular disorders.
•(9) Information in patient history or during physical examination indicating psychiatric disorders or substance abuse.
•(10) Information in patient history or during physical examination that the screening physician deems relevant for participation in the study.

发起方

Rigshospitalet Glostrup